⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGMB News
AgomAb Therapeutics NV American Depositary Shares
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
globenewswire.com
AGMB
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
globenewswire.com
AGMB
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
globenewswire.com
AGMB
Agomab Announces Closing of Initial Public Offering
globenewswire.com
AGMB
Agomab Announces Pricing of Initial Public Offering
globenewswire.com
AGMB